ribosomal protein lateral stalk subunit P1 pseudogene 13Genealiases: []
Q-omics provides the consensus-scored RPLP1P13 profile across patient tissues and cancer cell-line models. RPLP1P13 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPLP1P13 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, RPLP1P13 RNA expression shows 10,697 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight ACC, HNSC, and KIRP as cancer lineages where RPLP1P13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPLP1P13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPLP1P13 survival associations across molecular data types. RPLP1P13 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPLP1P13 RNA expression–survival associations across cancer types. High RPLP1P13 expression shows unfavorable associations in ACC, KIRC, COAD, PAAD and MESO, but favorable associations in BRCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RPLP1P13 RNA expression.
This table summarizes RPLP1P13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for RPLP1P13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPLP1P13 shows higher tumor expression in HNSC, COAD, KIRP, LIHC, KIRC and CHOL. The HNSC box plot shows higher RPLP1P13 RNA expression in tumor versus normal tissue (log2 FC = +0.211, t-test p = .003).
This table shows molecular features associated with RPLP1P13 in patient tissues and cancer cell lines. In patient samples, RPLP1P13 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set.
